



January 22, 2025

Dear Biopharm and mRNA Professional -

In the span of just two decades, messenger RNAs (mRNAs) have gone from biological proof-of-concept to an essential and growing class of therapeutics and vaccines. The discovery of nucleoside modifications which bypassed the inflammatory response opened the door to mRNAs as a new modality, its possibilities best exemplified by the remarkable development and global adoption of mRNA vaccines against COVID-19. Today, sponsors are developing mRNA vaccines against a wide array of infectious diseases, and many are exploring the application of mRNA agents for indications such as cystic fibrosis, metabolic diseases, and cancer.

We are delighted to present a program partnership invitation for the **Symposium on mRNA Therapy Products: Manufacturing, Quality, and Regulatory Considerations** to be held **May 29-30, 2025**, at the Gaithersburg Marriott Washingtonian Center in Gaithersburg, MD, USA. This symposium will bring together industry, academia, and regulatory agencies from around the world to explore, among other topics, how mRNA has become a new modality, how mRNA vaccines are applied against a wide array of infectious diseases, and how many are exploring the application of mRNA agents for other diseases. The symposia will be held in-person and is organized by *CASSS-Sharing Science Solutions*, a nonprofit professional association designed to provide educational and networking opportunities for biopharm separation and analytical scientists throughout the world, and the *Alliance for mRNA Medicines (AMM)*, the leading global organization dedicated to advancing and advocating for mRNA and next-generation encoding RNA therapeutics and vaccines for the benefit of patients, public health, and society.

**On behalf of CASSS and AMM, we hope that your company will become a prominent mRNA Symposium partner by contributing funds to offset part of the meeting expenses.** These partnerships are essential to the quality of the program and the interactions among attendees at the symposium.

The partnership levels are:

<b>DIAMOND PROGRAM PARTNER</b>	<b>\$25,000</b>	Includes eight (8) in-person badges, recognition on the website and mobile app, final program, and signage
<b>PLATINUM PROGRAM PARTNER</b>	<b>\$20,000</b>	Includes six (6) in-person badges, recognition on the website and mobile app, final program, and signage
<b>GOLD PROGRAM PARTNER</b>	<b>\$15,000</b>	Includes five (5) in-person badges, recognition on the website, final program, and signage
<b>SILVER PROGRAM PARTNER</b>	<b>\$9,500</b>	Includes three (3) in-person badges, recognition on the website and mobile app, final program, and signage

For acknowledgement of your company, please confirm your partnership by or before **Friday, May 2, 2025**. Thank you for your support of this important Symposium on mRNA Therapy Products. For additional information on the program, please visit <https://www.casss.org/mRNA>. To sign up as a program partner, please contact Kellie Greene Bailey, CASSS Program Manager, at [kgbailey@casss.org](mailto:kgbailey@casss.org) or 510.428.0740 ext. 819.

Thank you,

David Bergeson, Ph.D., CAE  
Executive Director  
CASSS

Clay Alspach  
Executive Director  
Alliance for mRNA Medicines